Enhabit Reports Third Quarter Financial Results

Company to host a conference call tomorrow, Nov. 2, 2022 at 10 AM EDT

DALLAS, November 01, 2022–(BUSINESS WIRE)–Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the third quarter ended September 30, 2022.

“We are making progress on our strategic initiatives,” Enhabit’s President and Chief Executive Officer, Barb Jacobsmeyer said. “During the quarter, labor constraints began to ease as our efforts around investment in our people began to take hold. We saw strong growth in Medicare Advantage admissions as we continued to expand in this growing part of our markets. The strategic and operational changes we are implementing in our hospice operations are having a positive impact as evidenced by our sequential growth in admissions and average daily census. We remain focused on the long-term growth of Enhabit.”

QUARTERLY PERFORMANCE – CONSOLIDATED

Consolidated third quarter 2022 results were impacted by the resumption of sequestration, continued shift to more non-episodic patients in home health, lower volumes in hospice, and higher cost of services related to labor, mileage reimbursement and fleet costs.

RECENT COMPANY HIGHLIGHTS

• Completed the acquisitions of Caring Hearts Hospice and Unity Hospice on October 1, 2022 and November 1, 2022, respectively, adding four locations in Texas and one in Arizona.

FINANCIAL RESULTS Consolidated
		Q3										’22 vs. ’21
($ in millions, except per share data)		2022					2021
Home health net service revenue		$			216.3		$			221.1		(2.2	) %
Hospice net service revenue					49.4					52.8		(6.4	) %
Total net service revenue		$			265.7		$			273.9		(3.0	) %
		% of Revenue					% of Revenue
Cost of services		49.8	%	$	(132.3	)	47.9	%	$	(131.2	)	0.8	%
Gross margin		50.2	%		133.4		52.1	%		142.7		(6.5	) %
Administrative & general expenses		38.2	%		(101.4	)	36.3	%		(99.4	)	2.0	%
Operating expenses		88.0	%	$	(233.7	)	84.2	%	$	(230.6	)	1.3	%
Equity earnings / noncontrolling interests					0.3					0.3
Adjusted EBITDA		$			31.7		$			43.0		(26.3	) %
Adjusted EBITDA margin					11.9	%				15.7	%
Adjusted EPS		$			0.19		$			0.50		(62.0	) %

The resumption of sequestration, continued shift to more non-episodic patients in home health, and lower volumes in hospice combined to decrease consolidated revenue by $15 million year over year.

Adjusted EBITDA decreased year over year primarily due to the resumption of sequestration; continued shift to more non-episodic patients in home health; lower volumes in hospice; higher costs of services related to labor; incremental costs associated with being a stand-alone company; and fleet and mileage reimbursement.

SEGMENT RESULTS Home health
		Q3						’22 vs. ’21
($ in millions)		2022			2021
Net service revenue		$	216.3		$	221.1		(2.2	) %
Cost of services			109.6			107.6		1.9	%
Gross margin			49.3	%		51.3	%
Adjusted EBITDA		$	44.6		$	51.2		(12.9	) %
% Adj. EBITDA margin			20.6	%		23.2	%
Operational metrics (Actual Amounts)
Starts of care
Episodic admissions			35,487			37,577		(5.6	) %
Non-episodic admissions			14,252			10,835		31.5	%
Total admissions			49,739			48,412		2.7	%
Same-store total admissions growth								1.3	%
Episodic recertifications			25,821			27,742		(6.9	) %
Non-episodic recertifications			6,541			5,200		25.8	%
Total recertifications			32,362			32,942		(1.8	) %
Same-store total recertifications growth								(2.4	) %
Total starts of care			82,101			81,354		0.9	%
Completed episodes			60,396			66,065		(8.6	) %
Revenue per episode		$	3,009		$	2,916		3.2	%
Visits per episode			14.9			15.0		(0.7	) %
Total visits			1,175,002			1,213,370		(3.2	) %
Non-episodic visits			272,282			220,260		23.6	%
Cost per visit		$	92		$	87		5.7	%

The year-over-year decrease in revenue was due primarily to the resumption of sequestration and continued payor mix shift to more non-episodic patients. Revenue per episode increased year over year primarily due to an increase in Medicare reimbursement rates, the timing of completed episodes, and patient mix under the Patient Driven Groupings Model offset by the resumption of sequestration.

Adjusted EBITDA decreased year over year primarily due to lower revenue and higher cost of services related to labor, fleet, mileage reimbursement, and workers’ compensation costs.

Hospice
		Q3						’22 vs. ’21
($ in millions)		2022			2021
Net service revenue		$	49.4		$	52.8		(6.4	) %
Cost of services			22.7			23.6		(3.8	) %
Gross margin			54.0	%		55.3	%
Adjusted EBITDA		$	9.3		$	13.1		(29.0	) %
% Adj. EBITDA margin			18.8	%		24.8	%
Operational metrics (Actual Amounts)
Total admissions			2,982			3,262		(8.6	) %
Same-store total admissions growth								(11.3	) %
Patient days			320,732			352,691		(9.1	) %
Discharged average length of stay			103			106		(2.8	) %
Average daily census			3,486			3,834		(9.1	) %
Revenue per day		$	154		$	150		2.7	%
Cost per day		$	71		$	67		6.0	%

The year-over-year decrease in revenue primarily was due to the decrease in average daily census and resumption of sequestration. Admissions increased sequentially from the second quarter of 2022 primarily due to improvements in staffing capacity and an increase in referral sources.

Adjusted EBITDA decreased year over year primarily due to lower revenue and higher cost of services related to labor (including increased use of contract labor), fleet, and mileage reimbursement.

GUIDANCE

The Company updated its full-year 2022 guidance as follows:

Full-year 2022	Revised Guidance	Prior Guidance
Net Service Revenue	between $1,070 and $1,080 million	between $1,075 and $1,110 million
Adjusted EBITDA	between $150 and $155 million	between $155 and $170 million
Adjusted EPS	between $1.37 and $1.50	between $1.47 and $1.75

For additional considerations regarding the Company’s 2022 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com. See also “Other Information” below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and Adjusted EPS.

CONFERENCE CALL INFORMATION

The Company will host an investor conference call at 10 AM Eastern Time on Nov. 2, 2022 to discuss its results for the third quarter of 2022. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting http://investors.ehab.com. Following the call, a replay will be available at the same location.

ABOUT ENHABIT HOME HEALTH & HOSPICE

Enhabit Home Health & Hospice is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 250 home health locations and 100 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

OTHER INFORMATION

Note regarding presentation of non-GAAP financial measures

The financial data contained in the press release and supplemental information includes non-GAAP financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted EPS, and adjusted free cash flow. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP are presented on the attached schedules.

However, the Company is unable to reconcile, without unreasonable effort, its guidance of Adjusted EBITDA and adjusted EPS to their corresponding GAAP measures due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Note regarding presentation of same-store comparisons

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited)
	Three Months Ended September 30,							Nine Months Ended September 30,
	2022			2021				2022			2021
	(In Millions, Except Per Share Data)
Net service revenue	$	265.7		$	273.9			$	808.0		$	830.5
Cost of service (excluding depreciation and amortization)		132.3			131.2				392.3			385.4
Gross margin		133.4			142.7				415.7			445.1
General and administrative expenses		107.5			104.2				310.4			309.8
Depreciation and amortization		8.0			9.4				24.7			27.9
Operating income		17.9			29.1				80.6			107.4
Interest expense and amortization of debt discounts and fees		6.2			0.1				6.3			0.2
Equity in net income of nonconsolidated affiliates		—			(0.1	)			—			(0.5	)
Other income		—			—				—			(1.6	)
Income before income taxes and noncontrolling interests		11.7			29.1				74.3			109.3
Income tax expense		2.8			7.1				17.9			26.2
Net income		8.9			22.0				56.4			83.1
Less: Net income attributable to noncontrolling interests		0.3			0.4				1.6			1.3
Net income attributable to Enhabit, Inc.	$	8.6		$	21.6			$	54.8		$	81.8
Weighted average common shares outstanding:
Basic		49.6			49.6				49.6			49.6
Diluted		49.7			49.6				49.7			49.6
Earnings per common share:
Basic earnings per share attributable to Enhabit, Inc. common stockholders	$	0.17		$	0.44			$	1.10		$	1.65
Diluted earnings per share attributable to Enhabit, Inc. common stockholders	$	0.17		$	0.44			$	1.10		$	1.65

Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited)
	September 30, 2022			December 31, 2021
	(In Millions)
Assets
Current assets:
Cash and cash equivalents	$	44.1		$	5.4
Restricted cash		3.8			2.6
Accounts receivable		148.8			164.5
Income tax receivable		7.9			—
Insurance settlement receivable		8.0			—
Prepaid insurance		3.8			2.5
Prepaid software and subscriptions		4.8			1.2
Prepaid expense and other current assets		4.5			2.6
Total current assets		225.7			178.8
Property and equipment, net		21.2			20.4
Operating lease right-of-use assets		41.6			48.4
Goodwill		1,217.7			1,189.0
Intangible assets, net		105.6			259.1
Other long-term assets		11.1			24.3
Total assets	$	1,622.9		$	1,720.0
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt	$	23.4		$	5.0
Current operating lease liabilities		13.9			14.9
Accounts payable		3.4			3.5
Accrued payroll		63.2			66.4
Refunds due patients and other third-party payors		11.7			12.2
Income tax payable		—			4.2
Insurance settlement payable		8.0			—
Accrued medical insurance		5.7			8.3
Accrued hospice expenses		5.3			4.2
Accrued other expenses		3.4			2.7
Other current liabilities		12.3			15.1
Total current liabilities		150.3			136.5
Long-term debt, net of current portion		545.2			3.5
Long-term operating lease liabilities		27.8			33.5
Deferred income tax liabilities		30.6			63.2
		753.9			236.7
Commitments and contingencies
Redeemable noncontrolling interests		5.2			5.0
Stockholders’ equity:
Enhabit, Inc. stockholders’ equity:		835.4			1,470.0
Noncontrolling interests		28.4			8.3
Total stockholders’ equity		863.8			1,478.3
Total liabilities and stockholders’ equity	$	1,622.9		$	1,720.0

Enhabit, Inc. and Subsidiaries Condensed Consolidated Cash Flows (Unaudited)
	Nine Months Ended September 30,
	2022				2021
	(In Millions)
Cash flows from operating activities:
Net income	$	56.4			$	83.1
Adjustments to reconcile net income to net cash provided by operating activities—
Depreciation and amortization		24.7				27.9
Amortization of debt related costs		0.3				—
Equity in net income of nonconsolidated affiliates		—				(0.5	)
Distributions from nonconsolidated affiliates		—				0.2
Stock-based compensation		7.1				2.1
Deferred tax (benefit) expense		(2.5	)			0.8
Other, net		—				(2.3	)
Changes in assets and liabilities, net of acquisitions—
Accounts receivable		16.4				(25.7	)
Prepaid expenses and other assets		(22.5	)			(0.2	)
Accounts payable		(0.2	)			(0.9	)
Accrued payroll		(3.3	)			14.0
Other liabilities		(0.4	)			1.7
Net cash provided by operating activities		76.0				100.2
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired		—				(97.7	)
Purchases of property and equipment		(5.3	)			(3.9	)
Additions to capitalized software costs		(0.5	)			(1.0	)
Other, net		1.7				2.9
Net cash used in investing activities		(4.1	)			(99.7	)
Cash flows from financing activities:
Principal borrowings on term loan		400.0				—
Principal payments on debt		(5.4	)			—
Borrowings on revolving credit facility		170.0				—
Principal payments under finance lease obligations		(3.6	)			(5.6	)
Debt issuance costs		(4.4	)			—
Distributions paid to noncontrolling interests of consolidated affiliates		(0.9	)			(1.6	)
Contributions from Encompass		59.8				91.8
Distributions to Encompass		(654.9	)			(93.7	…